Robust Growth in the Geographic Atrophy Market Driven by Aging Population and Technological AdvancesPune, Sept. 20, 2024 ...

The following is a summary of “Frequency and Longitudinal Course of Behavioral and Neuropsychiatric Symptoms in Participants ...

Delays in treatment for the rare genetic condition could lead to progressive muscle weakness and irreversible loss in motor ...

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA). According to the company, additional data from its Phase 2 ARCHER ...

A large, retrospective analysis of patients with amyotrophic lateral sclerosis (ALS) and progressive muscular atrophy (PMA) indicates that a substantial proportion of PMA patients develop upper ...

This CHMP opinion was made despite broad support for pegcetacoplan from the European retina community and multiple dissenting votes by CHMP members who supported a path to approval.” “We have seen the ...

Apellis Pharmaceuticals, Inc. (APLS) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of the ...

Phase 3 SAGA trial has revealed that Gildeuretinol clinically, meaningfully and safely reduced geographic atrophy lesions ...

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), ...

Michael L. Krychman, MD; Jan L. Shifren, MD, NCMP; James H. Liu, MD; Sheryl L. Kingsberg, PhD; Wulf H. Utian, MB BCh, PhD, DSc(Med), FRCOG, FACOG, FICS ...

A weight-maintaining hormone is essential for brain-signal transmission. New research is more closely linking obesity to ...

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...